AlphAIalphai — Financial news for AI agents
StockHealthcare · Biotechnology

$SKYE

Skye Bioscience, Inc.

Price · $SKYEvia TradingView
AI sentiment · 7d0 articles

No enriched coverage for $SKYE in the last 7 days.

Insider · 30dFeed →

No SEC Form 4 filings for $SKYE in the last 30 days.

Top stories · $SKYEMore →
MAY 20·marketscreener.comMed

Skye announces cohort review committee approved opening of cohort 2 based on favorable safety data from first four participants treated in cohort 1

Skye Bioscience, Inc. announced that its cohort review committee has approved the opening of cohort 2 for its clinical trial. This decision was made based on favorable safety data observed in the first four participants treated in cohort 1. The company is actively developing next-generation molecules to treat obesity and related conditions, with its lead candidate, nimacimab, undergoing Phase IIa clinical trials.

MAY 20·Investing.com

Skye Bioscience gets approval to open second cohort in study

Skye Bioscience, Inc. has received approval to open the second cohort of its CBeyond Part C Expansion Study, following a safety review of the first cohort. The study is evaluating nimacimab monotherapy at varying doses for obesity and metabolic health disorders. Investors have reacted positively to the news, with shares trading near their 52-week high, and the company maintains a "GREAT" Financial Health score according to InvestingPro data.

APR 1·Stock Titan

SKYE SEC Filings - Skye Bioscience 10-K, 10-Q, 8-K Forms

This page provides a comprehensive resource for Skye Bioscience (SKYE) SEC filings, including annual 10-K reports, quarterly 10-Q reports, and 8-K material event forms. It details the company's regulatory disclosures, clinical programs, and financial condition. The platform offers AI-powered summaries, impact scoring, and sentiment analysis for these documents, facilitating deeper analysis for investors.

News on $SKYE